Provided are immunostimulatory bacteria and pharmaceutical compositions containing the bacteria. The immunostimulatory bacteria provided herein contain one or more modalities that enhance the anti-tumor activity of the immunostimulatory bacteria. Among the immunostimulatory bacteria provided are bacteria, such as Salmonella species, which are modified to be auxotrophic or are auxotrophic for adenosine and/or contain plasmids encoding RNAi, such as shRNA and microRNA, that mediate gene disruption and/or expression of immune checkpoints, such as TREX1, VISTA, PD-L1 and, genes that influence the immune system. The bacteria contain additional modifications to enhance their anti-tumor activity. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the pharmaceutical compositions.

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

Provided are bacterial minicells derived from genome reduced (GR) having a reduced number of expressed genes and/or is a bacterium having one or more mutated min genes. In some embodiments, the minicell has a recombinant protein present in and/or on the surface of the minicell. In some embodiments, the recombinant protein is an antigen and in some embodiments, the minicell induces an enhanced immune response against the antigen when administered to a subject. In some embodiments, the bacterium has an autotransporter (AT) expression vector encoding the recombinant protein to express the recombinant protein on the surface of the bacterium and/or the minicell derived therefrom. Also provided are vaccine compositions that include bacterial minicells, methods for producing antibodies, methods for vaccinating subjects, and expression vectors encoding heterologous proteins.

The present invention relates to an inert carrier Salmonella and potential use thereof, which is expected to be developed into a new inert carrier bacteria, and can be applied to the development of an indirect agglutination test method for simple and rapid detection of antigens or infected antibodies. The inert carrier Salmonella has been deposited in CGMCC in Beijing on Mar. 18, 2019 with the accession number of CGMCC No.17340, and is classified as Salmonella sp.with a strain code of S9. The Salmonella has no visible agglutination reaction with various chicken sera derived from different genetic backgrounds, i.e., it has no non-specific agglutination reaction with chicken sera derived from broad range of genetic backgrounds.

Disclosed herein are methods and kits for quantifying the presence of a microorganism in a sample. Specifically, disclosed are methods for quantifying a pathogen in a sample, such as a food sample, to determine if the levels of pathogen present in the sample are within an acceptable range.

Described within is a new much improved host-vector systems for delivery of synthesized antigens or of DNA vaccines to a diversity of animal and human hosts to elicit immune responses, especially protective immune responses to control infection and disease induction and/or transmission by bacterial, viral, parasite and fungal infectious disease agents.

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

What is disclosed relates to the detection and identification of bacteria of the genera Salmonella and Shigella. It relates more precisely to the methods of microbiology and the culture media used for the detection, identification, isolation and/or analytical investigation of these bacteria. Relating to a method for enrichment and selective culture of bacteria of the genera Salmonella and/or Shigella contained in a biological sample. In the method, some or all of the sample is seeded in/on a culture medium including a nutrient component that favors the development and growth of the bacteria, and includes L-ornithine as a selective agent. It also covers a culture medium suitable for carrying out this method.

The present invention relates to the field of microbial growth, more specifically microbial overgrowth, even more specifically overgrowth of Enterobacteriaceae, specifically under conditions of apoptosis in the gut such as IBD, colitis, chemotherapy and food borne bacterial infections. The present invention provides inhibitors of a bacterial target, pyruvate formate lyase, which can be used to regulate the overgrowth of Enterobacteriacea.

Bacterial strains are provided having at least one enhanced mechanism to sequester, bind, precipitate, chemically oxidize or reduce copper ions or other toxic divalent transition metals. The bacteria may also have optional copper resistance mechanisms. The bacteria reduce the amount of available copper to tissues, which may be cancerous tissues, and reduce tumor growth, angiogenesis and/or metastasis, or tissues subject to excess copper due to host defects in copper metabolism. The bacteria are useful for treatment of neoplastic diseases including solid tumors and lymphomas, as well as Wilson's Disease, Menke's Disease, and possible Alzheimer's Disease, Parkinson's Disease, and Creutzfeld-Jakob Disease.